Ovarian Cancer: New PARP Therapy Can Be Discontinued After 7.5 Years
Long-term maintenance treatment with PARP inhibitors for patients with advanced ovarian cancer may be safely discontinued after seven and a half years, according to new clinical findings presented at the European Society for Medical Oncology (ESMO) Congress. This data provides a significant clinical benchmark for clinicians managing patients who have achieved long-term remission through targeted … Read more